CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
5.6282
2.92%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.2636
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 5.4782
Open* 5.6282
1-Year Change* 505.9%
Day's Range* 5.6282 - 5.6482
52 wk Range 0.43-1.29
Average Volume (10 days) 51.19K
Average Volume (3 months) 1.30M
Market Cap 23.64M
P/E Ratio -100.00K
Shares Outstanding 41.48M
Revenue 254.00K
EPS -0.73
Dividend (Yield %) N/A
Beta 1.38
Next Earnings Date Feb 12, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 5.4782 0.0600 1.11% 5.4182 5.5082 5.4182
Apr 11, 2024 5.9182 0.2400 4.23% 5.6782 6.0282 5.4482
Apr 10, 2024 6.0482 0.6800 12.67% 5.3682 6.1782 5.3682
Apr 9, 2024 5.6182 0.0900 1.63% 5.5282 5.8382 5.4582
Apr 8, 2024 5.4582 -0.5000 -8.39% 5.9582 6.0582 5.2082
Apr 5, 2024 5.3582 0.5500 11.44% 4.8082 5.5282 4.7282
Apr 4, 2024 4.9182 -0.1000 -1.99% 5.0182 5.0382 4.5382
Apr 3, 2024 5.2382 -0.1700 -3.14% 5.4082 5.4082 4.9482
Apr 2, 2024 5.5082 0.0000 0.00% 5.5082 5.7482 5.3982
Apr 1, 2024 5.8882 -0.4718 -7.42% 6.3600 6.3600 5.4982
Mar 28, 2024 0.7950 -0.0548 -6.45% 0.8498 0.8498 0.7061
Mar 27, 2024 0.8532 -0.0414 -4.63% 0.8946 0.9642 0.8216
Mar 26, 2024 1.0082 0.0637 6.74% 0.9445 1.0182 0.9444
Mar 25, 2024 0.9245 -0.0012 -0.13% 0.9257 0.9644 0.8967
Mar 22, 2024 0.9245 0.0099 1.08% 0.9146 0.9382 0.9146
Mar 21, 2024 0.9082 -0.0213 -2.29% 0.9295 0.9582 0.8946
Mar 20, 2024 0.9252 -0.0065 -0.70% 0.9317 0.9395 0.8778
Mar 19, 2024 0.9316 -0.0128 -1.36% 0.9444 0.9594 0.9245
Mar 18, 2024 0.9576 -0.0068 -0.71% 0.9644 0.9644 0.9291
Mar 15, 2024 0.9743 0.0299 3.17% 0.9444 0.9843 0.9444

Pluri Inc. Events

Time (UTC) Country Event
Friday, April 26, 2024

Time (UTC)

14:00

Country

IL

Event

Pluri Inc Annual Shareholders Meeting
Pluri Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, May 8, 2024

Time (UTC)

20:00

Country

IL

Event

Q3 2024 Pluri Inc Earnings Release
Q3 2024 Pluri Inc Earnings Release

Forecast

-

Previous

-
Tuesday, September 10, 2024

Time (UTC)

20:00

Country

IL

Event

Full Year 2024 Pluri Inc Earnings Release
Full Year 2024 Pluri Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 0.287 0.234 0 0.023 0.054
Revenue 0.287 0.234 0 0.023 0.054
Cost of Revenue, Total 0.009 0 0 0.002
Gross Profit 0.278 0 0.023 0.052
Total Operating Expense 27.533 41.827 50.623 29.499 35.586
Selling/General/Admin. Expenses, Total 11.779 17.45 20.557 7.922 9.157
Research & Development 17.413 13.501 13.47 21.643 12.841
Depreciation / Amortization 0.964 1.252 1.453 1.841
Other Operating Expenses, Total -1.668 9.912 15.344 -1.519 11.745
Operating Income -27.246 -41.593 -50.623 -29.476 -35.532
Interest Income (Expense), Net Non-Operating -1.625 0.244 0.781 0.356 0.105
Other, Net -0.016 -0.025 -0.023 -0.032 0.12
Net Income Before Taxes -28.887 -41.374 -49.865 -29.152 -35.307
Net Income After Taxes -28.887 -41.374 -49.865 -29.152 -35.307
Net Income Before Extra. Items -28.887 -41.374 -49.865 -29.152 -35.307
Net Income -28.887 -41.374 -49.865 -29.152 -35.307
Income Available to Common Excl. Extra. Items -28.887 -41.374 -49.865 -29.152 -35.307
Income Available to Common Incl. Extra. Items -28.887 -41.374 -49.865 -29.152 -35.307
Diluted Net Income -28.887 -41.374 -49.865 -29.152 -35.307
Diluted Weighted Average Shares 36.652 32.1921 28.1136 18.1973 1.23329
Diluted EPS Excluding Extraordinary Items -0.78814 -1.28522 -1.77369 -1.602 -28.6283
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.76817 -1.25929 -1.74709 -1.5688 -28.1158
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.111 0.087 0.002 0.087 0
Revenue 0.111 0.087 0.002 0.087 0
Cost of Revenue, Total 0.009
Gross Profit 0.102
Total Operating Expense 6.655 7.187 6.681 7.01 8.882
Selling/General/Admin. Expenses, Total 3.124 3.02 2.896 2.74 3.521
Research & Development 4.001 4.333 4.575 4.503 5.4
Other Operating Expenses, Total -0.479 -0.166 -0.79 -0.233 -0.039
Operating Income -6.544 -7.1 -6.679 -6.923 -8.882
Interest Income (Expense), Net Non-Operating -0.062 -0.217 -0.212 -0.194 -0.202
Net Income Before Taxes -6.606 -7.758 -8.254 -6.269 -9.084
Net Income After Taxes -6.606 -7.758 -8.254 -6.269 -9.084
Net Income Before Extra. Items -6.606 -7.758 -8.254 -6.269 -9.084
Net Income -6.606 -7.758 -8.254 -6.269 -9.084
Income Available to Common Excl. Extra. Items -6.606 -7.758 -8.254 -6.269 -9.084
Income Available to Common Incl. Extra. Items -6.606 -7.758 -8.254 -6.269 -9.084
Diluted Net Income -6.606 -7.758 -8.254 -6.269 -9.084
Diluted Weighted Average Shares 40.957 39.9476 33.1946 32.5626 32.3738
Diluted EPS Excluding Extraordinary Items -0.16129 -0.1942 -0.24865 -0.19252 -0.2806
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.16129 -0.1942 -0.24865 -0.19252 -0.2806
Other, Net -0.441 -1.363 0.848
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 41.409 57.747 67.371 48.461 26.371
Cash and Short Term Investments 40.171 55.016 64.95 45.784 23.705
Cash & Equivalents 5.36 9.772 31.241 8.27 4.106
Short Term Investments 34.811 45.244 33.709 37.514 19.599
Total Receivables, Net 0.527 1.321 1.49 1.61 1.421
Accounts Receivable - Trade, Net 0.25 0.955 1.108 1.248 1.243
Prepaid Expenses 0.442 0.403 0.333 0.445 0.532
Other Current Assets, Total 0.269 1.007 0.598 0.622 0.713
Total Assets 50.797 68.065 93.538 65.532 31.31
Property/Plant/Equipment, Total - Net 8.321 9.009 2.227 3.775 3.838
Property/Plant/Equipment, Total - Gross 25.768 26.094 18.259 18.437 17.004
Accumulated Depreciation, Total -17.447 -17.085 -16.032 -14.662 -13.166
Long Term Investments 0 23.269 12.653 0.398
Other Long Term Assets, Total 1.067 1.309 0.671 0.643 0.703
Total Current Liabilities 5.621 6.829 11.517 7.987 8.158
Accounts Payable 1.812 1.785 2.526 1.968 2.281
Accrued Expenses 3.665 4.475 8.951 5.893 5.637
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.144 0.569 0.04 0.126 0.24
Total Liabilities 37.442 38.026 36.387 9.431 9.489
Total Long Term Debt 23.53 21.678 23.85 0 0
Other Liabilities, Total 6.346 7.372 1.02 1.444 1.331
Total Equity 13.355 30.039 57.151 56.101 21.821
Common Stock 0.00041 0.00033 0.001
Additional Paid-In Capital 412.939 401.302 387.172 336.257 272.824
Retained Earnings (Accumulated Deficit) -399.584 -371.263 -330.021 -280.156 -251.004
Unrealized Gain (Loss)
Other Equity, Total -0.00041 -0.00033
Total Liabilities & Shareholders’ Equity 50.797 68.065 93.538 65.532 31.31
Total Common Shares Outstanding 41.2455 32.5075 31.9578 25.4927 15.0829
Long Term Debt 23.53 21.678 23.85
Minority Interest 1.945 2.147
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 35.258 41.409 46.687 50.14 49.723
Cash and Short Term Investments 33.609 40.171 44.168 47.246 48.015
Cash & Equivalents 5.253 5.36 3.677 8.818 8.744
Short Term Investments 28.356 34.811 40.491 38.428 39.271
Other Current Assets, Total 1.649 1.128 0.273 0.753 0.653
Total Assets 44.542 50.797 56.241 59.927 59.754
Property/Plant/Equipment, Total - Net 8.24 8.321 8.482 8.55 8.781
Long Term Investments
Other Long Term Assets, Total 1.044 1.067 1.072 1.237 1.25
Total Current Liabilities 4.322 5.621 5.377 5.284 5.018
Accounts Payable 0.973 1.812 1.453 1.257 1.329
Accrued Expenses 2.356 2.709 2.772 2.93 2.397
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.993 1.1 1.152 1.097 1.292
Total Liabilities 35.641 37.442 37.177 36.736 35.562
Total Long Term Debt 23.172 23.53 23.346 22.675 20.722
Other Liabilities, Total 6.01 6.346 6.637 7.002 7.113
Total Equity 8.901 13.355 19.064 23.191 24.192
Additional Paid-In Capital 413.446 412.939 412.189 408.692 401.576
Retained Earnings (Accumulated Deficit) -404.545 -399.584 -393.125 -385.501 -377.384
Total Liabilities & Shareholders’ Equity 44.542 50.797 56.241 59.927 59.754
Total Common Shares Outstanding 41.4485 41.2455 41.0722 38.2911 32.6347
Total Receivables, Net 0.11
Accounts Receivable - Trade, Net
Current Port. of LT Debt/Capital Leases
Long Term Debt 23.172 23.53 23.346 22.675 20.722
Common Stock 0.00041 0.00041 0.00041 0.00038 0.00033
Other Equity, Total -0.00041 -0.00041 -0.00041 -0.00038 -0.00033
Minority Interest 2.137 1.945 1.817 1.775 2.709
Prepaid Expenses 2.246 2.141 1.055
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -41.374 -49.865 -29.152 -35.307 -26.126
Cash From Operating Activities -36.501 -30.91 -26.369 -29.453 -21.38
Cash From Operating Activities 1.053 1.37 1.57 1.962 2.018
Non-Cash Items 8.909 13.968 2.562 5.146 -1.025
Cash Taxes Paid 0.01 0.01 0.027
Changes in Working Capital -5.089 3.617 -1.349 -1.254 3.753
Cash From Investing Activities 11.783 -7.265 -30.458 1.17 5.681
Capital Expenditures -0.28 -0.373 -0.27 -0.239 -0.342
Other Investing Cash Flow Items, Total 12.063 -6.892 -30.188 1.409 6.023
Cash From Financing Activities 7.5 61.402 60.87 23.582 19.921
Issuance (Retirement) of Stock, Net 0 36.953 60.87 23.475 19.833
Net Change in Cash -20.425 22.609 4.043 -4.701 4.222
Financing Cash Flow Items 7.5 0 0.107 0.088
Issuance (Retirement) of Debt, Net 0 24.449
Foreign Exchange Effects -3.207 -0.618
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -22.281 -14.523 -6.269 -41.374 -32.29
Cash From Operating Activities -19.96 -13.889 -7.609 -36.501 -28.074
Cash From Operating Activities 0.285 0.197 0.1 1.053 0.915
Non-Cash Items 2.942 1.897 0.984 8.909 7.782
Cash Taxes Paid
Changes in Working Capital -0.906 -1.46 -2.424 -5.089 -4.481
Cash From Investing Activities 5.374 7.062 6.393 11.783 14.738
Capital Expenditures -0.165 -0.141 -0.073 -0.28 -0.081
Other Investing Cash Flow Items, Total 5.539 7.203 6.466 12.063 14.819
Cash From Financing Activities 8.034 5.693 7.5 7.5
Issuance (Retirement) of Stock, Net 8.034 5.693 0 0
Net Change in Cash -6.83 -1.245 -1.382 -20.425 -6.908
Issuance (Retirement) of Debt, Net 0
Foreign Exchange Effects -0.278 -0.111 -0.166 -3.207 -1.072
Financing Cash Flow Items 0 7.5 7.5

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Pluri Inc. Company profile

About Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Financial summary

BRIEF: For the six months ended 31 December 2021, Pluristem Therapeutics Inc. revenues was not reported. Net loss increased 6% to $22.4M. Higher net loss reflects General and administrative expenses increase of 30% to $4.8M (expense), Stock-based Compensation in SGA increase of 9% to $4.6M (expense), Research & Development Expense decrease of 75% to $72K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to -$0.70.

Equity composition

Common Stock $0.00001 Par, 01/13, 100M auth., 58,333,206 issd. Insiders control 11.74%. IPO: NA. 11/07,1-for-200 reverse stock split. 11/07, Name changed from Pluristem Life Systems, Inc. 12/07, Exchanged changed from OTC Bulletin Board to NASDAQ.

Industry: Biotechnology & Medical Research (NEC)

Matam Park Building 5
HAIFA
3508409
IL

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

XRP/USD

0.50 Price
+0.980% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

17,753.10 Price
-1.600% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,092.61 Price
+0.350% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

63,759.60 Price
-0.650% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading